| scholarly article | Q13442814 |
| P2093 | author name string | Jeremy A Ross | |
| Robert A Kirken | |||
| G Steven Martinez | |||
| P2860 | cites work | JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model | Q28109595 |
| Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways | Q33787804 | ||
| Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials | Q34483765 | ||
| Array-based genomic resequencing of human leukemia | Q34618836 | ||
| Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies | Q35956625 | ||
| Interleukin-2 Receptor β Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules. | Q35978264 | ||
| Phosphorylation of human Jak3 at tyrosines 904 and 939 positively regulates its activity | Q36498064 | ||
| JAK mutations in high-risk childhood acute lymphoblastic leukemia | Q37224111 | ||
| Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies | Q37695012 | ||
| Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside | Q38543700 | ||
| Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma | Q39329997 | ||
| Activating alleles of JAK3 in acute megakaryoblastic leukemia | Q40255542 | ||
| The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities | Q40370385 | ||
| Cancer incidence among Hispanic children in the United States | Q40396503 | ||
| Racial and ethnic differences in survival of children with acute lymphoblastic leukemia | Q40637235 | ||
| Rising rates of acute lymphoblastic leukemia in Hispanic children: trends in incidence from 1992 to 2011. | Q42564155 | ||
| Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia | Q44998179 | ||
| SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia | Q46333198 | ||
| Trends in leukemia incidence and survival in the United States (1973–1998) | Q50718276 | ||
| Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma. | Q54342283 | ||
| Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. | Q54447711 | ||
| JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults | Q79657116 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 131-137 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Clinical cancer drugs | Q27727308 |
| P1476 | title | Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors | |
| P478 | volume | 3 |
| Q58742961 | Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma | cites work | P2860 |
Search more.